Related Experiment Video
Updated: Jul 21, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial
S C Grant1, L Kostakoglu, M G Kris
1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Abstract:
The present study evaluated the ability of the anti-GD2 ganglioside monoclonal antibody 3F8 to target tumor sites in patients with small-cell lung cancer (SCLC). Of 12 patients entered into the trial, ten received intravenous 3F8 labeled with 2 or 10 mCi iodine-131. The first five patients had recurrent or progressive disease after chemotherapy. Subsequent patients were studied before starting chemotherapy. Radionuclide scans were performed on days 1, 2, and 3 post-infusion and once between day 5 and day 7. Four patients underwent single-photon emission tomography (SPET) imaging. Radionuclide scans demonstrated localization to all known sites of disease, other than small brain metastases in one patient. SPET/CT scan fusion images confirmed precise localization. No significant toxicity was observed. Mean serum half-life was 64.2 h. Analysis of specimens from one patient who died of unrelated causes 6 days post-infusion confirmed the scan results. The present study demonstrates that 3F8 targets SCLC sites in patients. Further studies of anti-GD2 antibodies with higher doses of antibody and radionuclide are warranted to evaluate their role in SCLC.
Insights
The anti-GD2 antibody 3F8 effectively targets tumor sites in patients with small-cell lung cancer (SCLC). This study shows promising results for 3F8's potential role in SCLC diagnostics and treatment.
Area of Science:
- Oncology
- Immunotherapy
- Nuclear Medicine
Background:
- Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with limited treatment options.
- Targeting tumor-specific antigens like GD2 ganglioside offers a potential therapeutic strategy.
- The anti-GD2 monoclonal antibody 3F8 has shown promise in other cancers.
Purpose of the Study:
- To evaluate the tumor-targeting ability of the anti-GD2 monoclonal antibody 3F8 in patients with small-cell lung cancer (SCLC).
- To assess the safety and biodistribution of iodine-131 labeled 3F8 in SCLC patients.
- To determine the potential role of 3F8 in SCLC diagnosis and management.
Main Methods:
- Twelve patients with SCLC were enrolled in the study.
- Ten patients received intravenous 3F8 labeled with iodine-131.
- Radionuclide scans and single-photon emission tomography (SPET)/CT imaging were performed at various time points post-infusion.
Main Results:
- Radionuclide scans demonstrated successful localization of 3F8 to known SCLC tumor sites in all patients, except for small brain metastases in one case.
- SPET/CT fusion images confirmed precise localization of the antibody to tumor sites.
- No significant toxicity was observed, and the mean serum half-life of 3F8 was 64.2 hours.
Conclusions:
- The anti-GD2 antibody 3F8 effectively targets SCLC tumor sites in patients.
- 3F8 shows potential as a diagnostic and potentially therapeutic agent for SCLC.
- Further studies with higher doses of 3F8 and radionuclides are warranted to explore its full role in SCLC management.
